Approval · Notice of Compliance 33948 · 2024
CONSTELLA: Notice of Compliance 33948
Issued September 5, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33948
- Date
- September 5, 2024
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of new pediatric indication: treatment of functional constipation (FC) in children and adolescents 6 to 17 years of age
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CONSTELLA | Not yet assigned | — |
Medicinal ingredients
- LINACLOTIDE 290 MCG per CAP
- LINACLOTIDE 145 MCG per CAP
- LINACLOTIDE 72 MCG per CAP